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Objective: Certain cytokines, especially those known as growth factors, have been
demonstrated to mediate or modulate burn wound healing. Experimental and clinical
evidence suggests that there are therapeutic advantages to the wound healing process
when these agents are utilized. Positive effects have been reported for 4 types of wounds
seen in the burn patient: partial-thickness wounds, full-thickness wounds, interstices of
meshed skin grafts, and skin graft donor sites. Methods: A comprehensive literature
search was performed using the MEDLINE, Ovid, and Web of Science databases to
identify pertinent articles regarding growth factors and other cytokines in burns and
wound healing. Results: The current knowledge about cytokine growth factors and their
potential therapeutic applications in burn wound healing are discussed and reviewed.
Conclusions:Platelet-derivedgrowthfactor,ﬁbroblastgrowthfactors,epidermalgrowth
factors, transforming growth factor alpha, vascular endothelial growth factor, insulin-
like growth factor I, nerve growth factor, transforming growth factor beta, granulocyte-
macrophage colony-stimulating factor, and amnion-derived cellular cytokine solution
have all been suggested to enhance the rate and quality of healing in 1 or more of these
wounds encountered in burn care.
Theisolationandinvestigationofaclassofregulatorypolypeptidesknownascytokine
growth factors and their role in wound healing began almost 30 years ago. However, their
potential as therapeutic agents in acute wound healing has yet to be realized, despite
experimentally and clinically demonstrated safety and efﬁcacy and extensive experience in
thetreatmentofchronicwounds.1-6 Burnwoundsrepresentthelargestofroutinelycared-for
wounds,andtheyremainasigniﬁcantclinicalproblemforbothcaregiversandpatients.The
promise of utilizing growth factors and other humoral agents in accelerating and enhancing
This paper was presented in part at The John A. Boswick, MD Burn and Wound Symposium, Maui, Hawaii,
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wound healing represents an important goal in burn wound care. This article reviews the
current literature regarding the use of platelet-derived growth factor (PDGF), ﬁbroblast
growth factors (FGB), epidermal growth factors (EGF), transforming growth factor alpha
(TGF-α), vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-
I), nerve growth factor (NGF), transforming growth factor beta (TGF-β), granulocyte-
macrophage colony-stimulating factor (GM-CSF), and amnion-derived cellular cytokine
solution (ACCS) as local and systemic agents in healing partial-thickness burn wounds,
full-thickness burn wounds, interstices of meshed skin grafts, and skin graft donor sites.
GROWTH FACTORS AND THEIR IMPLICATIONS IN WOUND HEALING
In the scope of wound healing, cytokine growth factors act to inﬂuence many processes
including the proliferation and migration of various cell types, chemotaxis of ﬁbroblasts
and inﬂammatory cells, endothelial cell stimulation and angiogenesis, production and re-
modeling of extracellular matrix, inhibiting apoptosis, and mediating the synthesis of other
cytokines and growth factors.3,5,7 The orderly, sequential progression through the stages of
wound healing requires a number of different cells, humoral factors, and other agents to
interact in such a way that timely and proper closure of the wound occurs. Aberrations in
any of these pathways may result in pathologic wound healing from chronic, nonhealing
wounds to keloid or hypertrophic scar formation.7 To this point, growth factors have been
implicated in mediating the normal healing process as well as playing a role in impaired
wound healing. For example, certain growth factors (PDGF and IGF-I) act to inhibit the
apoptosis pathways necessary for the rapid turnover of cells required to facilitate the dif-
ferent stages of physiologic wound healing.7 The positive and negative effects of growth
factors in wound healing must, therefore, be taken into consideration for therapeutic ap-
plications. While there is a theoretical concern for oncogenesis secondary to growth factor
therapy, tumor development has not been seen in clinical or experimental studies to our
knowledge.
Platelet-derivedgrowthfactorisakeymediatorinwoundhealing,anditsimportanceis
highlightedinthatitwastheﬁrstrecombinantgrowthfactorapprovedfortopicalapplication
to accelerate wound closure.1,8 Platelet-derived growth factor is released by platelets and
secreted by activated macrophages with concentrations greatest in the early stages of the
injury response, peaking by day 3.9-13 However, PDGF plays a role throughout the entire
process of wound healing. In the beginning, PDGF serves as a chemoattractant for the
migration of ﬁbroblasts, neutrophils, and monocytes to the site of injury.3,14 Platelet-
derived growth factor is also a mitogen for ﬁbroblasts and promotes the production of new
extracellular matrix components.14,15 Later in the proliferative phase, PDGF stimulates
the differentiation of ﬁbroblasts into myoﬁbroblasts, promoting contraction of collagen
matrices and the wound.14-16 Platelet-derived growth factor has also been implicated in the
remodeling phase through its effect on stimulating collagenase production in ﬁbroblasts.16
Of the 3 isoforms of PDGF identiﬁed, PDGF-BB has been found to be the most beneﬁcial
for wound healing.17,18
Fibroblast growth factors constitute a large family of mitogens affecting a multitude
of cell types with important implications for wound healing.8,14,19 In wounds, expres-
sion of FGF detected by immunohistochemical methods is greatest at the center with
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progressive decline in intensity toward the periphery and almost none found in uninjured
skin.20 Acidic ﬁbroblast growth factor (aFGF) and basic ﬁbroblast growth factor (bFGF)
have been identiﬁed in wound ﬂuid, particularly at the earliest stages of healing.8,9,13,20-25
Basic FGF was further demonstrated to derive from ﬁbroblasts in cultured skin substitutes
(CSS).26 The role ofbFGF in wound healinghasbeenshown invitroand invivothroughits
actionsonearlylocalmacrophageactivation,augmentingproductionofextracellularmatrix
components, proliferation and differentiation of neuroectodermal and mesodermal deriva-
tives, ﬁbroblast proliferation, endothelial cell proliferation and migration for angiogenesis,
and reepithelialization.3,24,27-30 The broadest experience with clinical trials of growth fac-
tor therapy in wound healing has been with bFGF.8 Acidic FGF, similar in its biologic
properties to bFGF, likewiseinﬂuences the proliferation of ﬁbroblastsand endothelialcells,
promoting wound healing and angiogenesis.31,32 Keratinocyte growth factor 1 (KGF-1),
another member of the FGF family, promotes reepithelialization through its effects on
the proliferation and differentiation of epithelial cells while inhibiting apoptosis.33,34 Ker-
atinocyte growth factor 2 (KGF-2) similarly affects reepithelialization but also stimulates
granulation tissue formation and collagen deposition in the healing wound.8,33,35 Further
evidence suggests that early induction of KGF expression may be of importance for the
rapid reepithelialization seen in normal wound healing.36
Epidermal growth factors comprise another family of mitogens found to be present
in wound ﬂuid and have signiﬁcant effects on wound healing.14,37-40 Epidermal growth
factor is mitogenic to epithelial, mesothelial, and endothelial cells, and it has been shown to
accelerate reepithelialization, increase proliferation and tensile strength of healed dermis,
and improve wound healing overall.3,38,39,41 Regarding burn wound healing, however, there
isconﬂictingevidenceaboutthepresenceofEGFinthewoundﬂuid.8,14 Twoothermembers
of the EGF family, heparin-binding epidermal growth factor (HB-EGF) and TGF-α,h a v e
been detected at signiﬁcant levels in burn wound ﬂuid.14,42,43 Evidence for the roles of HB-
EGF and TGF-α in wound healing is seen through their effects on stimulating keratinocyte
proliferation and accelerating reepithelialization.37,42 Heparin-binding epidermal growth
factorisalsoamitogenforﬁbroblastsandactstostimulategranulationtissueformation.14,43
Vascular endothelial growth factors include a family of cytokine growth factors
identiﬁed as important mediators of angiogenesis, lymphangiogenesis, and vascular
permeability.44-49 Recent evidence suggests that the proangiogenic effects of VEGF may
be mediatedthrough the stimulationof hydrogen sulﬁde synthesisfrom endothelialcells,in
turnpromotingtheirproliferation,migration,andpermeability.46,49,50 Therearealsodatato
support the role of VEGF in stimulating epithelialization and collagen deposition.51 After
injury, the expression of VEGF from wounded cells is signiﬁcantly increased as part of the
physiologic response, and the same effect can be induced experimentally from quiescent
cells through direct exposure to serum, EGF, KGF, TGF-β1, and tumor necrosis factor
alpha.52 Several studies have demonstrated the beneﬁt of exogenous VEGF therapy on
accelerating and enhancing wound healing through topical application, ampliﬁed expres-
sion,andadenovirus-vectorgenetransferofthegrowthfactor.53-56 Conversely,neutralizing
antibodies to VEGF-A signiﬁcantly decreased wound ﬂuid accumulation, granulation tis-
sue formation, and angiogenesis, further evidence for the role of VEGF (VEGF-A, in
particular) in wound healing.46,57 Two other VEGF family members, VEGF-C and VEGF-
D, are involved in regulating lymphangiogenesis but not angiogenesis.14,58 The importance
of lymphatic vasculature in wound healing is demonstrated through its presence in formed
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granulation tissue and insufﬁciency in chronic wounds with impaired healing.45,58 While
VEGFappearstobebeneﬁcialinpromotingburnwoundhealing,acaveattothisisevidence
suggesting that the increased serum level of VEGF is responsible for the edema, anasarca,
and edema-associated complications after burn injury.46
Insulin-like growth factors I and II are well-described proanabolic and anticatabolic
agents that act on a multitude of cell types systemically.14,59 The positive anabolic and
wound healing effects of growth hormone (GH) appear to be directly and indirectly associ-
ated IGF-1 expression.3,59-66 In the scope of wound healing, evidence suggests that IGF-I
is mitogenic for keratinocytes and ﬁbroblasts, inhibits apoptosis pathways, attenuates pro-
and anti-inﬂammatory cytokine production, and stimulates extracellular matrix component
production.67-70 IGF-I is found in burn wound ﬂuid as part of the normal injury response,
and the expression of IGF-I and IGF-II has been shown to be signiﬁcantly upregulated
in epidermal cells of healing wounds that normally express minimal amounts of the pro-
tein product.14,71,72 In addition, the levels of IGF-I in wound ﬂuid demonstrate a positive
correlation with the success of wound healing.73
Nerve growth factor has been demonstrated to affect multiple aspects of wound
healing.14,74 Given the variety of neurogenically mediated processes involved in wound
healing, cutaneous nerve growth and restoration of normal innervation regulated by NGF
are essential to the normal healing process.74,75 Sensory nerves are responsible for re-
leasing substance P, a neuropeptide associated with stimulating epithelial proliferation and
migration and accelerating wound healing in a murine model when applied topically.75-77
Nerve growth factor has also been found to have proliferative and antiapoptotic effects on
keratinocytes and endothelial cells and to promote ﬁbroblast migration.78-80 Through its
proinﬂammatory effects on neutrophils, eosinophils, mast cells, and T lymphocytes, NGF
may serve to enhance the injury response as well.79
The TGF-β family is composed of many members with a great diversity in their
actions.14,81 Of particular interest to wound healing, the TGF-β1, TGF-β2, and TGF-β3
isoforms have been found to share a number of functions such as stimulating the prolif-
eration and production of ﬁbroblasts, extracellular matrix components, and cell adhesion
molecules,whileinhibitingthatofkeratinocytesandmostothercells.3,8,82-86 Earlyevidence
on TGF-β suggested that these factors were involved in accelerating reepithelialization and
enhancing wound healing. In a rodent partial-thickness injury model, TGF-β1 expression
was observed to share a close spatial and temporal correlation with the progression of
wound healing.87 TGF-β1 was also found to promote keratinocyte migration and epithe-
lial regeneration through enhancing integrin production and binding of keratinocytes to
ﬁbronectin and vitronectin.84,85,88 This suggested an overall positive effect on reepithe-
lialization despite the antiproliferative effects of TGF-β1 on keratinocytes.88 Accordingly,
TGF-β1-deﬁcient mice were found to have poor wound healing with impaired granulation
tissue formation, extracellular matrix production, and reepithelialization.89 Interestingly,
another study identiﬁed that TGF-β1 deﬁciency was associated with delays in wound heal-
ing only if TGF-β2 and TGF-β3 were not expressed.81 However, there is recent evidence
suggestingthatTGF-β1andTGF-β2negativelyinﬂuencewoundhealingthroughretarding
reepithelialization and increasing scar formation and contraction.90,91 TGF-β1 and TGF-
β2 have been implicated in keloid development after discovery of their overexpression
in these tissues.92,93 As TGF-β also serves as an anti-inﬂammatory agent, any state of
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persistent or increased inﬂammation such as infection or protracted healing may lead to
overexpression of TGF-β and subsequent keloid or hypertrophic scar formation.7 On the
contrary, fetal wounds that are less prone to cutaneous scarring are associated with low
levels of TGF-β1 and TGF-β2.14,94,95 These ﬁndings are further supported by evidence
from studies on TGF-β1 and TGF-β2 antagonism.90 Intradermal injection of neutralizing
antibodies to TGF-β1 alone or TGF-β1 and TGF-β2 was associated with reduced scarring
and wound contraction.96−98 The use of a synthetic TGF-β peptagonist applied locally
was found to accelerate reepithelialization, enhance overall wound healing, and decrease
scar formation and contracture in rabbit excisional and porcine burn and excisional wound
models.91,99 Contrary to the negative effects of TGF-β1 and TGF-β2, TGF-β3 appears to
be beneﬁcial for improving wound healing.95 The expression of TGF-β3i sh i g hi nf e t a l
wounds compared to adult wounds that are more prone to scarring.94 Experimental models
ofTGF-β3deﬁciencyanddeletiondemonstrateddelayedwoundhealingandincreasedscar
formation.95,100 Conversely, the therapeutic use of recombinant human TGF-β3( A v o t e r -
min, Juvista, Renovo Group, Manchester, United Kingdom) has been found to accelerate
wound healing and improve the appearance of cutaneous scarring postoperatively.95
Granulocyte-macrophage colony-stimulating factor is a multipotential cytokine with
many diverse functions.101-103 In the scope of burn injury, the beneﬁt of GM-CSF is 2-fold.
It has positive effects on enhancing wound healing and also acts to promote and restore
an impaired immune response.103 In normal circumstances, GM-CSF is only minimally
expressed by keratinocytes.104,105 However, signiﬁcant upregulation and production of this
cytokinefromkeratinocytes,ﬁbroblasts,endothelialcells,macrophages,anddendriticcells
occur shortly after tissue injury as part of the wound healing process.8,104-110 Granulocyte-
macrophage colony-stimulating factor has been shown to accelerate reepithelialization,
promote neovascularization, and improve the quality and quantity of granulation tissue
formation through increasing keratinocyte and endothelial cell proliferation, migration,
and survival.101,102,106,107,111,112 While GM-CSF is also known to affect ﬁbroblasts, its role
intissueremodelingiscomplex,andthereisconﬂictingevidenceaboutitsbeneﬁt.102,113-116
Granulocyte-macrophagecolony-stimulatingfactorplaysanimportantpartinmediatingthe
production and release of other cytokines and growth factors as well.101,102 The stimulation
of interferon-γ, interleukin-6, and TGF-β1 has demonstrated value in accelerating and
enhancing wound healing.101 Decreased synthesis of IL-2, as well as impaired T cell and
granulocyte proliferation and function, has been associated with thermal injury leading to
a weakened immune response.117-121 Granulocyte-macrophage colony-stimulating factor
has been shown to restore these immune deﬁcits, suggesting an additional role for its use
in burns to decrease morbidity and mortality from infectious complications.121,122
To this point, the discussion has focused upon growth factors and cytokines and their
applications in wound healing on an individual level. The normal wound healing process,
however,involvesacomplexseriesofinteractionsamongadiversepopulationofcelltypes,
growth factors, cytokines, and other mediators in a sequential fashion.3,67,123,124 There is
evidence to suggest that the use of combination or sequential cytokine agent therapy is
beneﬁcial for wound healing.125 One such combination is the autologous platelet product
of platelet-derived wound healing factors (PDWHF) as reported by Knighton et al.126,127
Platelet-derived wound healing factor is prepared from the isolation of platelet α-granule
products from platelet-rich plasma separated from patient whole blood.126 Administered as
a topical salve, PDWHF was found to be efﬁcacious in promoting the healing of chronic
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nonhealing wounds secondary to a number of disease processes.126 However, there are lim-
itations to PDWHF including the need for dilution in buffered saline and the requirement
for supraphysiologic concentrations of growth factors and cytokines required for thera-
peutic effect.124,126 Another combination therapy, ACCS, has been studied experimentally
and demonstrated to be valuable in several wound healing applications.125,128-130 Amnion-
derivedcellularcytokinesolutionisthecytokine-richproductsecretedfromamnion-derived
multipotent progenitor (AMP) cells.124,131 Initially, the use of AMP cells on laparotomy
wound healing in a rodent model was found to increase the gain of incisional breaking
strength and decrease the incidence and severity of acute wound failure.131 The production
of ACCS from these AMP cells was thought to be one possible mechanism of this beneﬁt.
Amnion-derived cellular cytokine solution is composed of a number of naturally appearing
growth factors and cytokines involved in normal wound healing at physiologic concentra-
tions, including PDGF, VEGF, TGF-β2, angiogenin, tissue inhibitor of metalloproteinase-1
(TIMP-1) and -2 (TIMP-2).124,129 Angiogenin plays an important role in angiogenesis
through activation of endothelial and smooth muscle cells to stimulate their proliferation,
migration, and invasion.132 TIMP-1 and TIMP-2 are particularly beneﬁcial for wound
healing through their effects on promoting cell proliferation, preventing apoptosis, and in-
hibiting matrix metalloproteinases (MMPs) that have been implicated in impeding wound
healing directly by destroying extracellular matrix proteins and indirectly through degrada-
tionofgrowthfactorsandcytokines.8,90,124,133 Thisisparticularlypertinentinburnwounds
associated with increased tissue proteolysis secondary to signiﬁcant upregulation of MMP-
1, MMP-3, and MMP-9 while TIMP-1 and TIMP-2 are relatively unaffected.134,135 Other
combination growth factors demonstrated to be of value in experimental wound healing
models include PDGF and TGF-α, PDGF and IGF, bFGF and IGF, PDGF and FGF, and
KGF- and IGF-1-cDNA transferred together.136-142 Live yeast cell derivative, an alcohol
extract from Saccharomyces cerevisiae, has also been demonstrated to improve burn and
other types of wound healing.143-145 However, the peptide portion of live yeast cell deriva-
tive implicated in wound healing does not appear to contain any of the described growth
factors and is signiﬁcantly less effective by comparison.143 The use of sequential cytokine
therapy has also been examined in chronic wounds using GM-CSF and bFGF therapy, but
the results of this study suggested that bFGF alone was more beneﬁcial than sequential
therapy.146
PARTIAL-THICKNESS BURN WOUNDS
Partial-thickness burn wounds are deﬁned as thermal injuries involving the epidermis and
variable thicknesses of dermis. Superﬁcial partial-thickness burn wounds are characterized
by injury limited to the upper third of the dermis, leaving a sufﬁcient blood supply to
the wound bed to facilitate proper wound healing.147 Deep partial-thickness burn wounds,
involving more of the dermal layer and a possible compromised blood supply, often give
rise to complications such as delayed wound healing, aberrant scarring, and contracture
formation.147 Growth factors and cytokines may be of therapeutic value with these types
of injuries to accelerate and enhance healing.90
Of the 4 types of burn wounds discussed in this article, partial-thickness burn wounds
have been the most extensively studied. In a prospective, randomized, placebo-controlled
trial, Fu et al148 showed that the use of recombinant bovine bFGF on superﬁcial and deep
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second-degree burn wounds improved healing time and quality. The time to healing was
shortened from 12.4 to 9.9 days (P = .0008) and from 21.2 to 17.0 days (P = .0003)
for superﬁcial and deep second-degree burns, respectively.148 Histologic evaluation of
these wounds revealed quantitativeand qualitative improvements in cellular differentiation,
angiogenesis, reepithelialization, and dermal-epidermal organization.148 Another prospec-
tive, randomized, placebo-controlled, double-blinded study examining topical recombinant
aFGF on deep partial-thickness burn injuries (and skin graft donor sites, discussed later)
demonstratedsigniﬁcantlyacceleratedhealingcomparedtoplacebo.31 Maetal31 notedthat
a higher percentage of wounds (71.79% vs 53.85%) were fully healed by 21 days postburn,
and the mean healing time was shorter (17.23 vs 18.92 days, P = .035). Akita et al149
found improved functional and aesthetic outcomes of burn wound scars with the use of
bFGF spray (Trafermin, Fiblast, Kaken Pharmaceutical, Tokyo, Japan) in pediatric patients
with superﬁcial and deep dermal burns. The function of the healed stratum corneum was
assessed using a moisture meter (ASA-M2, Asahi Biomed, Co Ltd, Yokohama, Japan)
that revealed decreased transepidermal water loss, increased epidermal water content, and
increased thickness of the layer.149 Clinical evaluation of scar quality using the Vancouver
Scar Scale based on pigmentation, pliability, height, and vascularity was signiﬁcantly im-
proved with bFGF therapy.149 A similar study by the same group examined the use of bFGF
spray and burn wound healing in adults with second-degree burns.30 Treatment with bFGF
again resulted in improved functional and aesthetic outcomes from the methods described
earlier as well as Cutometer and durometer measurements of scar elasticity and hardness,
respectively.30 Thereareotherclinicaltrialsintheliteraturedescribingthebeneﬁcialeffects
of bFGF on partial-thickness burn wound healing. One study demonstrated that treatment
of cells in a healing wound with gene gun-mediated delivery of the human bFGF gene
shortened complete healing time by 1.75 days (P <. 05).150 Nie et al151 showed that topi-
cal oxygen therapy supplementing bFGF application accelerated deep second-degree burn
wound healing. In addition, the use of bovine amnion in conjunction with topical recom-
binant bovine bFGF was found to decrease healing time for deep partial-thickness burn
wounds.152
In 1986, Brown et al153 demonstratedthat the use of topicallyappliedEGF accelerated
epidermal regeneration in porcine models of split-thickness wounds and partial-thickness
burns. With the use of biosynthetic human EGF in silver sulfadiazine, complete epidermal
regeneration was evidenced by day 7 while very little was seen in untreated burns or those
treated with silver sulfadiazine alone.153 Cribbs et al37 showed that topical application
of recombinant heparin-binding EGF in cholesterol-lecithin pellets signiﬁcantly increased
keratinocyte proliferation, enhanced endogenous TGF-α production, and accelerated reep-
ithelialization in the decreasing mean wound area from 6.0 cm2 to 1.07 cm2 in treated mice
compared with 2.20 cm2 in controls (P = .04) by postburn day 5. In a study by Jahovic
etal,40 EGFwasimplicatedasanimportantfactorintheimprovedwoundhealingassociated
with saliva and wound licking. Epithelial disruption, dermal edema, follicular destruction,
and myeloperoxidase activity (an indicator of neutrophil-mediated impairment of wound
healing) were similarly and signiﬁcantly decreased in rodent burn wounds treated with
EGF alone and EGF combined with permitted wound licking.40 The beneﬁcial effects of
exogenous EGF were further demonstrated by Alemdaro˘ glu et al39 in a study comparing
chitosan gel with and without EGF supplementation in rodent deep second-degree burn
wounds compared to EGF solution alone, silver sulfadiazine alone, and no treatment. In
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this comparison, wound healing was improved in the EGF-supplemented chitosan gel and
EGF-alone groups, with the most beneﬁt seen in the former.39 On histologic assessment
at day 14 postburn, the degree of cellular proliferation, epidermal thickness, and ﬁbroblast
maturation and differentiation were signiﬁcantly better in these study groups, reﬂecting the
effect of EGF in acceleratingand enhancingburn wound healing.39 In a relatedstudy by the
same group, EGF-containing liposomes were found to increase the rate of wound healing
by the same measures described previously.38 Guo et al154 demonstrated that application
of recombinant EGF on elderly burn patients decreased wound healing time from 16.22 to
14.3 days and from 29.13 to 26.11 days (P <. 05) in superﬁcial and deep second-degree
burns, respectively. In addition, the use of an EGF-impregnated collagen sponge dressing
for deep second-degree burns on a rabbit ear model was shown to enhance dermal matrix
formation, wound breaking strength, and skin resilience, and decrease the rate of wound
contraction.155
EvidenceforVEGFasavaluableagentinpartial-thicknessburnwoundhealingcomes
from a study by Galeano et al.55 Through the use of a recombinant adeno-associated vi-
ral vector-mediated human VEGF (rAAV-VEGF165) gene transfer mechanism, injection
of the rAAV-VEGF165 construct into the wounds of mice was found to enhance VEGF
expression with an associated increase in epidermal and dermal proliferation and regener-
ation, angiogenesis, ﬁbroblast proliferation, and maturation of the extracellular matrix.55
Erythropoietin,whichinteractswithVEGFandstimulatesendothelialcellproliferationand
migration, may also have a role as a wound healing agent.156 The same group demonstrated
subcutaneous administration of recombinant human erythropoietin (rHuEPO) in mice in-
creased epithelial proliferation, angiogenesis, extracellular matrix formation, and VEGF
levels locally.156 This was associated with signiﬁcantly increased reepithelialization and
accelerated time to complete wound closure in 19 days (vs 23 and 24 days in controls and
anti-rHuEPO-treated mice, respectively).156
The use of a TGF-β antagonist has been shown to positively affect partial-thickness
burn wound healing.91 Singer et al91 demonstrated that treatment with a topical TGF-
β peptagonist compared to carboxy methylcellulose, its vehicle, resulted in accelerated
reepithelialization (90% vs 45% completely reepithelialized at 14 days, P = .002) and
reduced scar formation and contraction in a porcine model. The proportion of contracted
wounds at 28 days was signiﬁcantly lower with TGF-β antagonist use (35% vs 65%,
P = .02).91 An adjunct to the consideration of TGF-β manipulation in burn wound healing
is Flightless I (Flii), an actin-remodeling protein that is upregulated in response to burn
injury.157 Adams et al157 found that the degree of Flii expression correlated positively
to TGF-β1 expression and negatively to that of TGF-β3. Through the use of neutralizing
antibodiestoFlii,partial-thicknessburnwoundhealinginmicewasfoundtobeaccelerated
with decreased remaining wound area when evaluated on day 14 posttreatment.157 This
was also associated with markedly reduced TGF-β1 and elevated TGF-β3 expression,
suggesting that these factors may contribute to the improved wound healing seen with Flii
attenuation.157
In a multicenter, randomized, double-blinded, stratiﬁed clinical trial, Zhang et al121
demonstrated that the topical application of a recombinant human GM-CSF (rhGM-CSF)
hydrogel compared to placebo yielded signiﬁcantly accelerated and enhanced partial-
thickness burn wound healing. Assessment of the extent of wound healing showed sig-
niﬁcant differences between the study groups at 14 (84.55% vs 44.44%), 20 (97.55% vs
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80.19%), and 28 (100.00 vs 96.67%) days after treatment.121 In addition, the time to com-
plete wound healing was found to be 14.71 versus 20.48 days in the treatment and control
groups, respectively.121 In a separate clinical trial, Wang et al158 demonstrated median
wound healing time to be decreased to 17 from 20 days and mean wound healing rate to be
higher at days 8, 14, 20, and 28 after treatment with rhGM-CSF versus placebo. Pooling
the results of these studies together, rhGM-CSF appears to signiﬁcantly accelerate deep
second-degree burn wound healing at 14, 20, and 28 days postburn.103
A number of combination growth factor and cytokine agents have been examined
in this setting. In a study of placental extracts and their effects on wound healing, Wu
et al159 found signiﬁcantly increased expression of TGF-β1 and bFGF and reduced time to
completewoundhealingof30dayscomparedwith52and62daysforuntreatedandnormal
saline treated rodents, respectively. Amniotic membrane (AM) products and derivatives
have also been studied as wound healing agents. Using human, bovine, and acellular
bovine AMs, Park et al160 demonstrated signiﬁcantly accelerated reepithelialization with
similar therapeutic efﬁcacy between each AM type by 14 days postinjury (76.85%-78.65%
in AM groups vs 17.6% in controls) in a porcine burn wound model. Payne et al125
demonstrated that the use of ACCS and AMP cells, as described previously in this article,
accelerated reepithelialization in guinea pig models of partial-thickness burn wounds. In
all but one ACCS-treated group, there was at least 90% wound reepithelialization by day
7 (vs 20%-40% in non-ACCS treatment groups, P <. 05).125 This beneﬁt was also found
to be directly proportionate to the dosing of ACCS as evidenced by improved results with
higher frequency ACCS application and the presence of AMP cells as a constant source
of ACCS.125 Regenerating agents (RGTAs), while not growth factors or cytokines in and
of themselves, have been found to accelerate and enhance wound healing.161 Engineered
as derivatives of dextran, RGTAs mimic heparan sulfate in the extracellular matrix, in
turn stabilizing and protecting matrix proteins and heparin-binding growth factors (FGF,
VEGF, PDGF, TGF-β).161 Zakine et al161 demonstrated that the use of RGTAs on deep
second-degree burn wounds accelerated reepithelialization, improved neovascularization,
and decreased the degree of dermal remodeling in a rodent model. However, the time to
complete reepithelialization of 7 days was not different between treatment and control
groups, althoughepidermalmaturationappeared more advancedwith theuse of RGTAs.161
FULL-THICKNESS BURN WOUNDS
As full-thickness burn wounds generally require excision and grafting, the utility of growth
factors and cytokines as wound healing agents alone is not substantial. The use of these
agents as adjuncts to skin grafting and donor site healing will be discussed later in this
article. Nevertheless, a small number of studies have demonstrated the potential value of
growth factor therapy in this setting.
In 1995, a comparison study between the effects of several different growth fac-
tors on deep partial-thickness and full-thickness burn wounds was reported by Danilenko
et al.162 Using porcine wound models, the group compared recombinant forms of EGF,
TGF-α, PDGF-BB, bFGF, KGF, and neu differentiation factor.162 Their evidence suggested
that signiﬁcant beneﬁt for full-thickness wounds was only seen with the combination of
rPDGF-BB enhancing extracellular matrix production and granulation tissue formation
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and rKGF increasing epithelialized area.162 For this same reason, rKGF was the only agent
shown to consistently improve deep partial-thickness burn wound healing.162
Jeschke et al34 demonstrated that KGF delivered through a nonviral liposomal cDNA
gene transfer mechanism signiﬁcantly increased skin cell proliferation and decreased apop-
tosis, improved epidermal and dermal regeneration, and enhanced neovascularization com-
pared to controls given only the delivery vehicle (liposomes plus LacZ gene construct) in
a rodent model. This beneﬁt was further supported in a similar study by Pereira et al.163
Liposomal KGF-cDNA gene transfer in a rodent scald burn model was found to improve
reepithelialization, dermal regeneration, and neovascularization through increased expres-
sion of IGF-I, IGF binding protein-3, FGF, and collagen type IV and decreased TGF-β
production.163 Through extensive experience by the group of Herndon and Jeschke, the use
of liposomal IGF-1-cDNA gene transfer has been demonstrated to consistently and sig-
niﬁcantly increase keratinocyte proliferation, accelerate reepithelialization and dermal re-
generation, increase serum and liver protein concentrations, and improve postinjury weight
gain in rodent models.141,164-168 This improvement was also seen to have a positive corre-
lation with increasing numbers of IGF-1-cDNA-containing liposome injections.164 These
beneﬁts of IGF-1-cDNA gene transfer were found to be associated with increased expres-
sion of IGF-I, FGF, KGF, VEGF, PDGF, and collagen type IV .169 Jeschke and Herndon142
further demonstrated the additional beneﬁt of combining KGF-cDNA and IGF-1-cDNA in
liposomal gene transfer constructs over either gene alone in a rodent model. Dermal and
epidermal regenerationwere signiﬁcantlyenhancedand associatedwith increasesin VEGF
expression and neovascularization.142
Similar to the study on partial-thickness burns by Singer et al,91 TGF-β peptagonist
treatment of full-thickness injuries was found to accelerate reepithelialization and reduce
scarring and contracture.99 Speciﬁcally, Huang et al99 demonstrated complete versus 70%
reepithelialization at day 26 and 50% versus 70% wound contraction at day 33 in treatment
and control groups, respectively. Scarring and visually apparent open wound areas were
also notably reduced with TGF-β peptagonist therapy.99
In the only human study of full-thickness burn wounds found in the literature, Weng
et al170 reported signiﬁcantly faster wound healing and lower infection rates with the use of
nanometer silver dressing and recombinant bovine FGF compared with saline and parafﬁn
absorbent gauze.
INTERSTICES OF MESHED SKIN GRAFTS
Thegoaloftreatmentforanyburninjuryistoachievesuccessfulclosureoftheburnwound.
For deeper burns requiring excision and affecting greater amounts of body surface area,
the use of meshed skin autografts has helped to overcome the problem of limited donor
site availability. However, meshed skin autografts do not impart immediate biologic wound
closure as their interstices remain open and expose the patient to metabolic, infectious, and
other complications of open burn wounds. The use of growth factor therapy in accelerating
the closure of meshed skin graft interstices would have signiﬁcant therapeutic beneﬁt in
this regard. In addition, functional and aesthetic improvements in healed skin graft quality
may be secondary beneﬁts of using these agents.
Smith et al171 investigated the effect of several growth factors and cytokines in
the closure of human meshed skin graft interstices on a “nude” rat model. Accelerated
438CHING ET AL
epithelialization and closure of graft interstices were demonstrated in wounds treated with
KGF-2,TGF-β2,andbFGFbutnotinterleukin-4,macrophagecolony-stimulatingfactor,or
KGF-1.171 By day 7, greater than 85% of graft interstices had closed with KGF-2, TGF-β2,
and bFGF treatment compared with 65% in controls. While complete closure was reached
in untreated controls and all treatment groups (except KGF-1) by day 11, this was achieved
in wounds treated with KGF-2 and TGF-β2 by day 9 postgrafting.171
The use of ACCS, a solution of multiple growth factors and cytokines as characterized
earlier, was demonstrated to accelerate closure of human meshed skin graft interstices
by Uberti et al.130 By day 9 postgrafting, 83.72% to 92.2% versus 67.03% (P <. 05) of
interstices were epithelialized in ACCS-treated and saline-treated grafts, respectively.130
There was no statistical difference seen between daily and alternate day dosing of ACCS
or if animal-derived components were a part of the formulation.130
Recently,Branskietal172 demonstratedthatthedeliveryofPDGF-cDNAvialiposomal
gene transfer was effective in accelerating reepithelialization and adhesion of meshed skin
grafts in a porcine burn wound model. In addition to reinforcing the value of PDGF in
the setting, this study further supports the possible use of liposomal gene transfer as an
effective mechanism for wound healing therapy in humans.172
In 2 separate studies, Akita et al173,174 demonstrated that exogenous bFGF appli-
cation improved the quality of and color uniformity in skin graft healing. Skin grafts
treated with bFGF were found to have accelerated wound healing, better color unifor-
mity with surrounding skin on color meter analysis, and signiﬁcantly decreased hard-
ness based on a clinical assessment-scoring system used in scleroderma and durometer
measurements.173,174
Evidence from these studies suggests that certain growth factors, namely bFGF, TGF-
β2, KGF-2, and ACCS, can accelerate epithelialization and closure of meshed skin graft
intersticesinburnwounds.Improvedskingrafthealingandsurvivalhavebeendemonstrated
instudiesonotherwoundmodels.Soleretal33showedacceleratedclosureofgraftinterstices
onarodentfull-thicknessexcisionalwoundmodelwithKGF-2therapy.Vascularendothelial
growth factor was found to signiﬁcantly decrease dermal necrosis and improve survival of
full-thickness skin grafts on rodent models in 2 separate, respective studies.175,176 Aside
from meshed skin grafts, burn wounds that require more extensive coverage have also been
addressed with the use of CSS, which are biopolymer matrices composed of keratinocytes
and ﬁbroblasts.177 The use of VEGF promoted angiogenesis and organization of murine
but not human endothelial cells in CSS grafted to an athymic mouse model, suggesting that
it plays a limited role on human endothelial cells and CSS with neovascularization.178 In
another study, the addition of bFGF to CSS grafted on immunodeﬁcient mice resulted in
signiﬁcantly enhanced angiogenesis and ﬁbroblast proliferation.177 Taken together, growth
factor therapy may not only accelerate closure of meshed skin graft interstices but also
enhance skin graft survival.
DONOR SITE WOUNDS
The requirement for skin grafting inevitably creates another wound to address, the donor
site wound. Conservative medical management generally proceeds without consequence.
However, accelerating and enhancing donor site wound healing are potentially beneﬁcial
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for reducing continued wound care needs and patient burden and in the setting of multiple
skin graftings and limited donor site availability. In the wound ﬂuid from split-thickness
skin graft donor sites of 24 patients, Ono et al10 demonstrated the consistent presence of
large amounts of PDGF, interleukin-6, TGF-α, and TGF-β and possibly small quanitities
of EGF and bFGF. Therefore, it stands to reason that the use of exogenous growth factor
therapy can be of value in the setting of donor site wound healing.
In 1989, Brown et al41 examined the use of EGF with silver sulfadiazene compared to
silver sulfadiazene alone in the treatment of split-thickness skin graft (0.015 in) donor site
woundsin12patients.Theaveragetimeto25%to50%and75%to100%reepithelialization
with adjunctive EGF was decreased by approximately 1 day and 1.5 days, respectively.41
Guo et al179 also found that using recombinant human EGF in dressing donor site wounds
accelerated reepithelialization and decreased wound healing time.
ThebeneﬁtofFGFondonorsitewoundhealinghasbeendemonstratedin2randomized
clinical trials. Ma et al31 found that topical recombinant aFGF decreased the mean healing
time of donor site wounds to 13.07 from 14.71 days (P <. 001). Recombinant bovine
bFGF was shown by Fu et al28 to accelerate healing of split-thickness skin graft (0.008-
0.01 in) donor site wounds from 14.74 to 10.68 days compared to placebo. However, an
earlier clinical study by Greenhalgh et al180 did not ﬁnd any improvement in the rate of
epithelializationortimetocompleteclosure(12.9vs12.2daysinbFGF-andplacebo-treated
wounds,respectively)withtheuseoftopicalrecombinanthumanbFGFonpartial-thickness
skin graft donor sites in children.
Herndonetal60 examinedtheeffectsofrecombinanthumangrowthhormone(rhGH)in
patientswithgreaterthan40%totalbodysurfacearea(TBSA)or20%TBSAfull-thickness
scald or ﬂame burns. No signiﬁcant differences in donor site healing were found between
subcutaneously administered placebo and rhGH at 0.1 mg/kg/d.60 However, when rhGH
was administered intramuscularly at 0.2 mg/kg/d, donor site healing time and overall length
of stay were decreased by 2 to 4 days and 0.8 days per percent TBSA burn, respectively.60
In a subsequent trial by the same group, the effects of rhGH at 0.2 mg/kg/d administered
subcutaneouslyinpatientswithgreaterthan40%TBSAfull-thicknessburnswasstudied.181
With rhGH treatment compared to placebo, coverage of the dermal-epidermal junction by
the basal lamina was increased to 68% from 26% at 7 days and mean healing time was
decreased to 5.6 days from 7.7 days (P <. 05).181 Associated increases in systemic IGF-1
levels and local expression of IGF-1 receptors, laminin, collagen types IV and VII, and
cytokeratin-14 were demonstrated and postulated to play direct roles in the enhancement of
donor site healing seen with GH administration.60,181 Another clinical trial by Gilpin et al61
demonstrated signiﬁcant beneﬁt, using 2 forms of rhGH in accelerating donor site healing
to 6.0 days with Protropin (Genentech, Inc, San Francisco, California) and 6.8 days with
Nutropin (Genentech, Inc) from 8.5 days with placebo (P < .01). While increased ﬁbrosis
and abnormal scarring have been associated with GH therapy in experimental studies, de
Oliveira et al182 and Barret et al183 did not ﬁnd any signiﬁcant adverse effects of rhGH on
human scar formation. In addition, Ramirez et al184 demonstrated rhGH therapy to be safe
and efﬁcacious in the treatment of severely burned children without signiﬁcant associated
increases in morbidity and mortality.
Bergmann et al128 did not ﬁnd signiﬁcant differences in the appearance or healing
time of partial-thickness donor site wounds treated with ACCS in diabetic and nondiabetic
pigs. The beneﬁt of ACCS treatment was seen on a microscopic level with a signiﬁcantly
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thicker epidermis and more cell layers and rete ridges in diabetic pigs whereas only more
rete ridges were seen in nondiabetic pigs.128
Evidence from the clinical trials described supports the use of growth factor therapy in
donor site wound healing. Taking into consideration the experimental success and potential
beneﬁt,furtherclinicaltrialsarewarrantedtoestablishtheroleofexogenousgrowthfactors
inthissetting.Whilecombinationgrowthfactortherapymayhavearoleindonorsitewound
healing, there is no strong evidence in the literature at this time.
CONCLUSION
Cytokine growth factors, including PDGF, FGB, EGF, TGF-α, VEGF, IGF-I, NGF, TGF-
β, GM-CSF, and ACCS, appear to accelerate and enhance wound healing through their
physiologicactionsandinﬂuences.Assuch,growthfactorsrepresentapromisingtreatment
to affect more rapid and effective closure of burn wounds and have shown positive results
in many instances experimentally. Although extensive human clinical data are lacking,
a number of studies demonstrate encouraging evidence with growth factor therapy in
accelerating and enhancing burn wound healing. Further clinical trials are warranted and
considerations for sequential growth factor application and/or growth factor cocktails may
prove to be more efﬁcacious than the application of a single growth factor.
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